Business
Co-hosts Dave Franchino and Stefanie Norvaisas talk with Kevin Conroy, President and CEO of Exact Sciences, a Madison-based biotech. Under Kevin’s leadership since 2009, the company has grown from three people to more than 4,200. Their flagship product, Cologuard, is a proprietary multi-marker test for the early detection of colorectal cancer. In this interview, Kevin talks about the challenges his company has faced during the pandemic and how they quickly developed a Covid-19 test and partnered with the state of Wisconsin to make it widely available. He also discusses the opportunities that the growing acceptance of telehealth is opening up directly reaching consumers and increasing the rate of screening.